Javier Cortés, MD, PhD, head of the International Breast Cancer Centre (IBCC), Barcelona, Spain, reviews subgroup analyses from the Phase 3 EMERALD trial. Professor Cortés discusses how these findings may inform clinical decision-making in the second-line setting, following endocrine therapy plus CDK4/6 inhibitor therapy, for patients with ESR1-mutated tumors.
More Videos in Metastatic Breast Cancer Content Hub
Exercise during curative chemotherapy for breast cancer has proven benefits. It helps reduce fatigue, preserve muscle strength, improve fitness, and enhance overall quality of life. Staying physically active…
Polly Niravath, MD, breast oncologist, Houston Methodist Cancer Center, Texas, discusses breast to brain metastasis. Dr Nirvath also reviews some available medications to treat brain metastases in patients…
Part 1 – Case Presentation Gabriel N. Mannis, MD, presents the case of patient “J.A.” to fellow faculty members Brian A. Jonas, MD, PhD, FACP, and Daniel A.…
In this video, Sarah DiGeronimo, NP, and Sydney Smith, PharmD, both from Dana-Farber Cancer Institute, Boston, Massachusetts, discuss tips for the management of common side effects resulting from…
Part 3 – Case Discussion & Wrap-up Gabriel N. Mannis, MD, presents the case of patient “J.A.” to fellow faculty members Brian A. Jonas, MD, PhD, FACP, and…
Tufia C. Haddad, MD, an oncologist at Mayo Clinic, Rochester, Minnesota, discusses what to expect before, during, and after initial treatment for metastatic breast cancer. Dr Haddad emphasizes…
Lobular breast cancer presents unique challenges in detection and treatment due to its diffuse growth pattern and differences from ductal cancers. Liz O’Riordan, MD, shares her personal journey,…
Sramila Aithal, MD, medical oncologist, Cancer Treatment Centers of America, discusses optimization of therapy for patients with HER2-positive metastatic breast cancer. Dr Authal shares her experience with toxicity…
